ERBB2 and breast carcinoma: This agent combines direct cytotoxicity with immune‐mediated activity and has shown promising efficacy in both HER2(+) and HER2(−) advanced breast cancer, with objective response rates (ORR) of 42.9 and 33.3%, respectively [130].